New pill could stop scarring hair loss in its tracks

NCT ID NCT07508488

Recruiting now Disease control Sponsor: Icahn School of Medicine at Mount Sinai Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 10, 2026 · Updated 2 times

Summary

This study tests a daily pill called deucravacitinib in 20 adults with two types of scarring hair loss (CCCA and FFA). The goal is to see if it can reduce inflammation and scarring on the scalp over 48 weeks. All participants receive the drug, and researchers will measure changes in immune markers and hair loss severity.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Deucravacitinib (a pill that targets inflammation)
What this could lead to: If it works, this could point toward a new treatment option for people with scarring hair loss, potentially slowing or stopping hair loss.
What could go wrong: This is a small, early-phase trial with only 20 participants and no placebo group. It mainly looks at biological markers, not hair regrowth, so results may not lead to a proven treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CENTRAL CENTRIFUGAL CICATRICIAL ALOPECIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

central centrifugal cicatricial alopecia frontal fibrosing alopecia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CENTRAL CENTRIFUGAL CICATRICIAL ALOPECIA FRONTAL FIBROSING ALOPECIA

Contacts and locations

Locations

Icahn School of Medicine at Mount Sinai
RECRUITING

New York, New York, 10029, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.